PRESS RELEASE: 'Corporate Reputation of Pharma, 2018 - the Perspective of Patient Groups Specialising in Autoimmune Conditions' 'Corporate Reputation of Pharma in 2018 - the Perspective of Autoimmune Patient Groups'
EMBARGOED PRESS RELEASE: 6am GMT, MONDAY, AUGUST 1st 2019 ~ Contact: Alex Wyke ~ Tel: +44-(0)7960-855-019 ~ Email: report@patient-view.com London, July 25th, 2019. ABOUT THIS REPORT AND SURVEY
AbbVie | Allergan | Almirall | Amgen | Astellas | AstraZeneca | Bayer | Biogen | Boehringer Ingelheim | Bristol-Myers Squibb | Celgene | Chiesi Farmaceutici | CSL Behring | Eli Lilly | Ferring | Gilead | Grünenthal | GSK | Janssen | LEO Pharma | Menarini | Merck & Co/MSD | Merck KGaA | Mundipharma | Novartis | Novo Nordisk | Octapharma | Pfizer | Pierre Fabre | Roche/Genentech | Sanofi | Servier | Takeda/Shire | Teva | UCB. The 2018 autoimmune corporate-reputation report contains three appendices: Appendix 1. Analyses of corporate reputation in the field of arthritis, 2018 v. 2017. Appendix 2. Analyses of corporate reputation in the field of psoriasis, 2018 v. 2017. And ... Appendix 3: Comments from 2018's respondent autoimmune patient groups on how pharma can improve (organised by country and condition). KEY FINDINGS ACROSS THE PHARMA INDUSTRY The corporate reputation of the pharmaceutical industry, 2017-2018, autoimmune patient groups v. patient groups from all therapy areas (percentage of respondent patient groups stating “Excellent” or “Good”) Autoimmune patient groups seem to take a more positive view of the pharma industry as a whole than their peer patient groups from other therapy areas [see nearby chart]. The percentage of autoimmune patient groups that thought pharma's corporate reputation "Excellent" or Good" in 2018 (47%) is slightly down on the equivalent figure from the previous year. Nevertheless, patient groups specialising in the various autoimmune conditions do hold differing views about the corporate reputation of the pharmaceutical industry. As shown in the chart below, psoriasis patient groups are the most positive about pharma (67% of them described the industry’s corporate reputation as “Excellent” or “Good” in 2018). The most negative about pharma among the autoimmune patient groups are coeliac patient groups (only 18% of them stated that the industry as a whole had an “Excellent” or “Good” corporate reputation in 2018). The corporate reputation of the pharmaceutical industry as a whole—comparing the views of different types of autoimmune patient groups (percentage of respondent autoimmune patient groups stating “Excellent” or “Good”) The diverse attitudes to pharma among autoimmune patient groups appear to be linked to levels of patient satisfaction with medical treatment—as is shown by the various categories of autoimmune patient groups that deem the industry to be making high-quality products for the patients of their subject field [see chart below]. The types of autoimmune patient groups that are the most positive about pharma's ability to create useful, high-quality products also tend to be those which rate the corporate reputation of the industry most highly. Effectiveness of pharma at supplying high-quality, useful products, 2018, as viewed by different types of autoimmune patient groups (percentage of respondent autoimmune patient groups stating “Excellent” or “Good”) Scleroderma patient groups are something of an exception, here; other factors seem to influence their views on pharma. The feedback received from the scleroderma patient groups responding to the 2018 Corporate-Reputation survey indicates that the main reason why only 30% of scleroderma patient groups regard the pharma industry’s corporate reputation as “Excellent” or “Good” is a perception among them that the industry is unwilling to support scleroderma patient groups. 2018's respondent scleroderma patient groups could point to just 3 of the 35 companies included in this 2018 autoimmune analysis as partnering with scleroderma patient groups (Bayer, Boehringer Ingelheim, and Janssen). Scleroderma patient groups call for greater support, on the basis that scleroderma is a rare condition.
“We know that the majority of our patients utilize, and rely on, medications produced by these companies. These companies continue to strive to provide more convenient and innovative methods of medication for patients.”
“Patient organisations and the patients they represent are an essential element of the strategies employed by pharma in getting drugs to market. However, unrestricted financial support is rare, but critical in the rare-disease community.”
HOW DID COMPANIES PERFORM? HOW CORPORATE REPUTATION IS MEASURED The overall corporate reputation of each company is assessed according to that company's performance (as judged by patient groups) at 12 individual indicators of corporate reputation. The TOP TEN companies for corporate reputation—from the perspective of autoimmune patient groups familiar with the company, 2018 v. 2017 The indicators [listed below] have been developed over the years by PatientView, drawing on recommendations from patient groups, health professionals, health regulators, and industry. The 12 indicators used to measure corporate reputation from the perspective of patient groups
The ARTHRITIS corporate-reputation rankings, 2018 [55 respondent arthritis patient groups]Companies ranking 1st among arthritis patient groups familiar with the company, 2018 AbbVie was ranked overall 1st out of 14 companies for corporate reputation in 2018, according to the 46 respondent arthritis patient groups familiar with the company. Pfizer was ranked 1st by arthritis patient groups for 4 of the individual indicators of corporate reputation [see table], and Roche was ranked 1st for one indicator. The PSORIASIS corporate-reputation rankings, 2018 [27 respondent psoriasis patient groups]Novartis was ranked overall 1st out of 7 companies for corporate reputation in 2018, according to the 27 respondent psoriasis patient groups familiar with the company. Janssen was ranked 1st by psoriasis patient groups for 4 of the individual indicators of corporate reputation [see table], and LEO Pharma was ranked 1st for 2 indicators. Companies ranking 1st among psoriasis patient groups familiar with the company, 2018 For further information on the 2018 AUTOIMMUNE report, please use contact details at the top of this press release ~END OF PRESS RELEASE~
|